167 related articles for article (PubMed ID: 16806484)
1. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.
Lim Z; Baker B; Zuckerman M; Wade JJ; Ceesay M; Ho AY; Devereux S; Mufti GJ; Pagliuca A
J Infect; 2007 Feb; 54(2):e83-6. PubMed ID: 16806484
[TBL] [Abstract][Full Text] [Related]
2. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
5. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival.
Lim ZY; Ingram W; Brand R; Akthari M; Milojkovic D; Ho AY; Devereux S; Pagliuca A; Duarte RF; Mufti GJ
Bone Marrow Transplant; 2007 Oct; 40(8):747-52. PubMed ID: 17704796
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
7. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
Song WK; Min YH; Kim YR; Lee SC
Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
[TBL] [Abstract][Full Text] [Related]
9. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab.
Oshima K; Sakata-Yanagimoto M; Asano-Mori Y; Izutsu K; Watanabe T; Shoda E; Ogawa S; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
Bone Marrow Transplant; 2005 Nov; 36(9):821-4. PubMed ID: 16113661
[TBL] [Abstract][Full Text] [Related]
10. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
11. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
13. Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.
Sive JI; Thomson KJ; Morris EC; Ward KN; Peggs KS
Clin Infect Dis; 2012 Nov; 55(10):1362-70. PubMed ID: 22903766
[TBL] [Abstract][Full Text] [Related]
14. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Nagi W; Lim ZY; Krishnamurthy P; Potter V; Tindell V; Reiff-Zall L; Abdullah A; Lea N; Kenyon M; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2011 Aug; 35(8):998-1000. PubMed ID: 21704371
[TBL] [Abstract][Full Text] [Related]
16. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients.
Unal E; Yen C; Saiman L; George D; Della-Latta P; van de Ven C; Morris E; Bradley MB; Del Toro G; Garvin J; Bhatia M; Schwartz J; Satwani P; Roman E; Cooney E; Wolownik K; Hawks R; Foley S; Cairo MS
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1188-97. PubMed ID: 17085312
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
18. Analysis of cerebral toxoplasmosis in a series of 170 allogeneic hematopoietic stem cell transplant patients.
Hakko E; Ozkan HA; Karaman K; Gulbas Z
Transpl Infect Dis; 2013 Dec; 15(6):575-80. PubMed ID: 24103000
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
20. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
